International Journal of Drug Policy
Volume 21, Issue 2 , Pages 97-99 , March 2010

Learning from HIV epidemics among injecting drug users

Received 15 September 2009 ,Revised 5 November 2009 ,Accepted 6 November 2009.

References 

  1. Beyrer C, Razak MH, Lisam K, Chen J, Lui W. Overland heroin trafficking routes and HIV-1 spread in South and Southeast Asia. AIDS. 2000;17(1):75–83
  2. Centers for Disease Control and Prevention . CDC HIV/AIDS. Atlanta, GA: Department of Health and Human Services; 2009;
  3. Choopanya K, Vanichseni S, Des Jarlais DC, Plangsringarm K, Sonchai W, Carballo M, et al. Risk factors and HIV seropositivity among injecting drug users in Bangkok. AIDS. 1991;5:1509–1513
  4. Craib KJ, Spittal PM, Wood E, Laliberte N, Hogg RS, Li K, et al. Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. Canadian Medical Association Journal. 2003;168:19–24
  5. Des Jarlais DC, Friedman SR, Novick DM, Sotheran JL, Thomas P, Yancovitz S, et al. HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987. Journal of the American Medical Association. 1989;261:1008–1012
  6. Des Jarlais DC, Hagan H, Friedman SR, Friedmann P, Goldberg D, Frischer M, et al. Maintaining low HIV seroprevalence in populations of injecting drug users. Journal Association Medical Association. 1995;274(15):1226–1231
  7. Des Jarlais DC, Perlis TP, Arasteh K, Torian LV, Beatrice S, Milliken J, et al. HIV incidence among injection drug users in New York City, 1990 to 2002: Use of serologic test algorithm to assess expansion of HIV prevention services. American Journal of Public Health. 2005;95(8):1439–1444
  8. Des Jarlais DC. Can HIV be eliminated among injecting drug users?. In: Presented at the 2009 national HIV prevention conference. Atlanta, GA, August 23–26. 2009;
  9. Des Jarlais DC, Arasteh A, Hagan H, McKnight C, Perlman DC, Friedman SR. Persistence and change in disparities in HIV infection among injecting drug users in New York City after large-scale syringe exchange. American Journal of Public Health. 2009;99(Suppl. 2):S445–S451
  10. Emmanuelli J, Desenclos JC. Harm reduction interventions, behaviours and associated health outcomes in France, 1996–2003. Addiction. 2005;100(11):1690–1700
  11. Friedman TL. The Lexus and the olive tree. New York: Anchor Books; 2000;
  12. Hammett TM, Wu Z, Duc TT, Stephens D, Sullivan S, Liu W, et al. ‘Social Evils’ and harm reduction: The evolving policy environment for human immunodeficiency virus prevention among injection drug users in China and Vietnam. Addiction. 2007;103:137–145
  13. Hacker MA, Leite I, Friedman SR, Carrijo RG, Bastos FI. Poverty, bridging between injecting drug users and the general population, and “interiorization” may explain the spread of HIV in southern Brazil. Health & Place. 2009;15:514–519
  14. Kabakchieva E, Vassileva S, Kelly JA, Amirkhanian YA, DiFranceisco WJ, McAuliffe TL, et al. HIV risk behavior patterns, predictors, and sexually transmitted disease prevalence in the social networks of young Roma (Gypsy) men in Sofia, Bulgaria. Sexually Transmitted Diseases. 2006;33:485–490
  15. Kaldor J, Elford J, Wodak A, Crofts JN, Kidd S. HIV prevalence among IDUs in Australia: A methodological review. Drug and Alcohol Review. 1993;12:175–184
  16. Omori K. Knowledge about AIDS and risk behaviors among hill tribes in northern Thailand. Nippon Koshu Eisei Zasshi. 1999;46:466–475
  17. Sanaullah F, Gillian M, Lavin TJ. Screening of substance misuse during early pregnancy in Blyth: An anonymous unlinked study. Journal of Obstetrics and Gynaecology. 2006;26(3):187–190
  18. Stimson GV. AIDS and injecting drug use in the United Kingdom, 1987–1993: The policy response and the prevention of the epidemic. Social Science & Medicine. 1995;41(5):699–716
  19. Stimson GV, Adelekan ML, Rhodes T. The diffusion of drug injection in developing countries. International Journal of Drug Policy. 1996;7:245–255
  20. In:  Stimson GV,  Des Jarlais DC,  Ball A editor. Drug injecting and HIV infection: Global dimensions and local responses. London: UCL Press; 1998;
  21. Stimson GV, Fitch C, Des Jarlais DC, Poznyak V, Perlis T, Oppenheimer E, et al. WHO Phase II Drug Injection Collaborative Study Group Rapid assessment and response studies of injection drug user: Knowledge gain, capacity building, and intervention development in a multisite study. American Journal of Public Health. 2006;96:288–295
  22. UNAIDS/WHO . AIDS epidemic update: December 2006. Geneva: Joint United Nations Programme on HIV/AIDS; 2007;
  23. Uüskula A, McNutt LA, Dehovitz J, Fischer K, Heimer R. High prevalence of blood-borne virus infections and high-risk behaviour among injecting drug users in Tallinn, Estonia. International Journal of STD and AIDS. 2007;18:41–46
  24. Zhang Y, Shan H, Trizzino J, Ruan Y, Beauchamp G, Masse B, et al. Demographic characteristics and risk behavior associated with HIV positive injecting drug users in Xinjiang, China. The Journal of Infection. 2007;54:285–290

PII: S0955-3959(09)00136-4

doi: 10.1016/j.drugpo.2009.11.001

International Journal of Drug Policy
Volume 21, Issue 2 , Pages 97-99 , March 2010

Article Tools